{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:24:49Z","timestamp":1785291889350,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The study aimed to estimate the cost\u2010effectiveness of <jats:italic>CYP2C19<\/jats:italic> genotype\u2010guided antiplatelet therapy using cilostazol and ticagrelor as an alternative to clopidogrel, compared to conventional antiplatelet therapy with clopidogrel and aspirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 90\u2010day decision tree and 30\u2010year Markov model were employed to assess the costs and quality\u2010adjusted life years (QALYs) of personalized antiplatelet therapy for patients with minor ischemic stroke and high\u2010risk transient ischemic attack, compared to conventional antiplatelet therapy in the Chinese healthcare system. The primary outcome was the incremental cost\u2010effectiveness ratio (ICER). The data sources included clinical trials, published literature, official documents and local prices. One\u2010way sensitivity analysis and probabilistic sensitivity analysis were performed to confirm the robustness of the findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base\u2010case analysis indicated that the <jats:italic>CYP2C19<\/jats:italic> genotype\u2010guided antiplatelet strategy was cost\u2010effective, and cilostazol group and ticagrelor group yielded an ICER of 3327.40 US dollars (USD)\/QALY and 3426.92 USD\/QALY, respectively, which were less than threshold. The one\u2010way sensitivity analysis showed the results were robust, where the most sensitive parameter was the disability distribution in the modified Rankin scale 3\u20105. The probabilistic analysis showed that the <jats:italic>CYP2C19<\/jats:italic> genotype\u2010guided antiplatelet therapy with either cilostazol or ticagrelor was 100% cost\u2010effective under the willingness\u2010to\u2010pay threshold.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:italic>CYP2C19<\/jats:italic> genotype\u2010guided antiplatelet therapy using\u00a0cilostazol and ticagrelor as an alternative to clopidogrel appeared to be more cost\u2010effective than conventional antiplatelet therapy for acute minor ischemic stroke and high\u2010risk transient ischemic attack patients over 30\u2009years in China.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15921","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T12:07:00Z","timestamp":1696507620000},"page":"483-492","source":"Crossref","is-referenced-by-count":6,"title":["Cost\u2010effectiveness analysis of <i>CYP2C19<\/i> genotype\u2010guided antiplatelet therapy for patients with acute minor ischemic stroke and high\u2010risk transient ischemic attack in China"],"prefix":"10.1111","volume":"90","author":[{"given":"Zhuolin","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Pharmacy Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Bao","sequence":"additional","affiliation":[{"name":"School of Health Policy and Management Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Gu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-8061","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy Nanjing Medical University  Nanjing China"},{"name":"School of Health Policy and Management Nanjing Medical University  Nanjing China"},{"name":"Center for Global Health, School of Public Health Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(04)00800\u20102"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00252\u20100"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440\u20101681.2009.05290.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)30427\u20101"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025250"},{"key":"e_1_2_10_7_1","first-page":"168","article-title":"Chinese classification of cerebrovascular diseases (2015)","volume":"50","author":"Chinese Society of Neurology, Chinese Stroke Society","year":"2017","journal-title":"Chin J Neurol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001665"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(18)30500\u20103"},{"key":"e_1_2_10_10_1","first-page":"379","article-title":"Prevalence of stroke\u2014United States, 2006\u20102010","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010019\u201009281\u20105"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.025464"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000190056.76543.eb"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010021\u201007010\u20101"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.08007"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.2020.111"},{"key":"e_1_2_10_17_1","unstructured":"XuJ.Research of medication compliance and efficacy in patients with secondary prevention of ischemic stroke and transient ischemic attack [master] 2016."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12329"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"e_1_2_10_20_1","first-page":"51","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018","author":"Chinese Society of Neurology, Chinese Stroke Society","year":"2018","journal-title":"Chin J Neurol"},{"key":"e_1_2_10_21_1","unstructured":"Pharmasolution.Top 50 by sales of drugs in sample hospitals in China in 2019.2020. Available fromhttps:\/\/mp.weixin.qq.com\/s\/d4jZXh0XViYLMyNAzMPDvw. Accessed Feb 28th 2022."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4588"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029132"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.000823"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2014.953044"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25535"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201086824\u20109"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105581"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(19)30148\u20106"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111749"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15542"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010020\u201000970\u2010y"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.70.453"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.94"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs\u20102019\u20100050"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.027980"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000912"},{"key":"e_1_2_10_39_1","volume-title":"China Health Statistics Yearbook","author":"China National Health Commission","year":"2021"},{"key":"e_1_2_10_40_1","first-page":"6","article-title":"The utilization of inpatient health services and influencing factors of hospitalization costs of urban stroke patients in China","volume":"23","author":"Yong Y","year":"2020","journal-title":"Chin Gen Pract"},{"key":"e_1_2_10_41_1","unstructured":"National Bureau of Statistics of the People's Republic of China. Available fromhttp:\/\/www.stats.gov.cn\/. Accessed Mar 26th 2022."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/svn\u20102020\u2010000737"},{"key":"e_1_2_10_43_1","volume-title":"China Guidelines for Pharmacoeconomic Evaluations (2020 Edition)","author":"Liu GG","year":"2020"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1543"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875\u20109114.2012.01048"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.164"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.01.044"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248420902298"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.2217\/pme\u20102022\u20100056"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2012.04788.x"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.18999\/nagjms.80.2.207"},{"key":"e_1_2_10_53_1","unstructured":"YangJ.The role of antiplatelet therapy strategy based on Thromboelastography on clinical outcomes in patients with HR\u2010NICE:Jilin University 2019."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T08:18:42Z","timestamp":1706602722000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/bcp.15921"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15921","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}